Clinical Trial With MSC for Graft Versus Host Disease Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

January 21, 2022

Study Completion Date

January 21, 2022

Conditions
Acute Graft Versus Host Disease
Interventions
DRUG

Adult Allogeneic Mesenchymal cells from adipose tissue.

"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"

Trial Locations (6)

30120

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

31008

Clinica Universitaria de Navarra, Av Pio XII ,36, Pamplona

37007

Hospital clinico universitario de salamanca, Salamanca

41013

Virgen del Rocio University Hospital, av. Manuel Siurot s/n, Seville

Unknown

Hospital Universitario Reina Sofía, Córdoba

Hospital Regional Universitario de Málaga, Málaga

All Listed Sponsors
collaborator

Andalusian Initiative for Advanced Therapies

OTHER_GOV

lead

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud

OTHER

NCT02687646 - Clinical Trial With MSC for Graft Versus Host Disease Treatment | Biotech Hunter | Biotech Hunter